

## Latest Development in Multiple Myeloma

Guest Editor:

**Dr. Yoichi Imai**

IMSUT Hospital, The Institute of  
Medical Science, The University  
of Tokyo, Tokyo, Japan

Deadline for manuscript  
submissions:

**closed (15 October 2019)**

### Message from the Guest Editor


Dear Colleagues,

Multiple myeloma is an incurable B-cell malignancy frequently accompanied by many complications, like osteolytic lesions and renal failures. In the age of novel anti-myeloma drugs, including proteasome inhibitors and immunomodulatory drugs, the response rate and survival duration have been improved. In addition, immunotherapy using therapeutic antibodies and CAR-T cells has led to a great advance in the treatment of relapse/refractory patients. This Special Issue will discuss recent developments in our understanding of the biology and genomic characteristics, detection of minimal residual disease, innovations in the field of multiple myeloma.

Assoc. Prof. Dr. Yoichi Imai

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)